FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a compound of formula I
and pharmaceutical compositions containing them and used for IAP-function modulation by inhibiting the binding of BIR-binding protein and BIR domain of IAP and for treating proliferative diseases such as cancer. What is also disclosed is a compound of formula I marked by a detectable tag and an affinity tag which is applicable as a probe for identifying the compounds bound with BIR domain of IAP.
EFFECT: preparing the compounds used for IAP-function modulation.
33 cl, 4 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS BINDING BTR DOMAIN OF IAP PROTEINS | 2007 |
|
RU2472780C2 |
COMPOUNDS BINDING IAP BIR DOMAINS | 2006 |
|
RU2418807C2 |
BIR DOMAIN IAP BINDING COMPOUNDS | 2011 |
|
RU2567544C2 |
IMIDAZOPYRIDINE IAP INHIBITORS | 2007 |
|
RU2466131C2 |
IAP INHIBITORS | 2006 |
|
RU2451025C2 |
IAP INHIBITORS | 2008 |
|
RU2491276C2 |
IAP INHIBITORS | 2005 |
|
RU2401840C2 |
IAP INHIBITORS | 2013 |
|
RU2593259C2 |
IAP INHIBITORS | 2013 |
|
RU2728789C2 |
COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
Authors
Dates
2012-03-27—Published
2007-05-16—Filed